-
公开(公告)号：WO2023018817A1
公开(公告)日：2023-02-16
申请号：PCT/US2022/039980
申请日：2022-08-10
申请人： SANOFI PASTEUR INC.
发明人： BARRO, Maro , CHAN, Yvonne , CORTES-GARCIA, Guadalupe , GOMILA, Raul , HAN, Liqun , KLEKOTA, Justin , MA, Fuqin , RAY, Satyajit , STEGALKINA, Svetlana , STRUGNELL, Tod , USTYUGOVA, Irina , VOGEL, Thorsten , ZHANG, Jianxin
IPC分类号： C07K14/11 , A61K39/12 , A61K39/145 , A61P31/16
摘要： Provided are modified influenza virus subtype 2 neuraminidase molecules lacking all or substantially all of the stalk region that form active, soluble tetrameric neuraminidase when expressed in host cells and vaccine compositions comprising the tetrameric neuraminidase or a nucleic acid encoding the modified monomeric influenza virus subtype 2 neuraminidase molecules that forms tetrameric NA when expressed in a cell. Also provided are methods of using the vaccine compositions to vaccinate or immunize a subject against influenza virus.
-
公开(公告)号：WO2022178196A1
公开(公告)日：2022-08-25
申请号：PCT/US2022/016894
申请日：2022-02-18
申请人： SANOFI PASTEUR INC.
发明人： ARNAUD-BARBE, Nadège , BALHARA, Vinod , IANTOMASI, Raffaella , KAZEK-DURET, Marie-Pierre , MCCLUSKEY, Jacqueline , QUEMENEUR, Laurence , ROKBI, Bachra , SHIVER, John
IPC分类号： A61K39/095 , A61P31/04 , C07K14/22
摘要： The present disclosure relates to an immunogenic composition comprising a combination of meningococcal antigens which comprises at least one factor H binding protein (fHBP) A protein, at least one fHBP B protein, at least one Neisseria adhesin A (NadA) protein, and at least one detergent-extracted Outer Membrane Vesicle (dOMV). The meningococcal antigens may be from a Neisseria meningitidis serogroup B. The combination of antigens provided a broad coverage of bacteria strains. Further, the present disclosure relates to the use of the immunogenic composition in methods for eliciting an immune response.
-
公开(公告)号：WO2021173907A1
公开(公告)日：2021-09-02
申请号：PCT/US2021/019781
申请日：2021-02-26
申请人： SANOFI PASTEUR, INC.
摘要： Disclosed herein are immunogenic compositions and vaccination regimes for immunizing humans against influenza disease.
-
公开(公告)号：WO2019152925A8
公开(公告)日：2019-08-08
申请号：PCT/US2019/016511
申请日：2019-02-04
发明人： AN, Kyungjun , HAM, Dongsoo , KIM, Hun , KIM, Sunghyun , SHIN, Jinhwan , HOPFER, Robert , KENSINGER, Richard, D. , KYAW, Moe , TALAGA, Philippe
IPC分类号： A61K39/02
摘要： Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM 197 , wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of two of serotypes 1, 3, and 5 and one or both of serotypes 15B and 22F are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM 197 . Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.
-
公开(公告)号：WO2019152925A1
公开(公告)日：2019-08-08
申请号：PCT/US2019/016511
申请日：2019-02-04
发明人： AN, Kyungjun , HAM, Dongsoo , KIM, Hun , KIM, Sunghyun , SHIN, Jinhwan , HOPFER, Robert , KENSINGER, Richard, D. , KYAW, Moe , TALAGA, Philippe
IPC分类号： A61K39/02
摘要： Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM 197 , wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of two of serotypes 1, 3, and 5 and one or both of serotypes 15B and 22F are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM 197 . Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.
-
6.发明申请
公开(公告)号：WO2018027123A1
公开(公告)日：2018-02-08
申请号：PCT/US2017/045479
申请日：2017-08-04
发明人： AN, Kyungjun , CHOI, Wooyoung , HAM, Dongsoo , KIM, Hun , SHIN, Jinhwan , HOPFER, Robert , KENSINGER, Richard, D. , KYAW, Moe , DESAUZIERS, Eric , EL GUERCHE SEBLAIN, Clotilde , TALAGA, Philippe
摘要： Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 16 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid or CRM 197 , wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 9V, 12F, 14, 18C, 19A, 19F, 22F, 23F, and 33F, wherein two of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRM 197 , and wherein the two capsular polysaccharides that are conjugated to tetanus toxoid are selected from the group consisting of serotypes 1, 3, and 5. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.
摘要翻译： 提供包含16种不同肺炎球菌荚膜多糖 - 蛋白质缀合物的混合载体，多价肺炎球菌缀合物组合物，其中每种缀合物包括来自与破伤风类毒素或CRM缀合的不同肺炎链球菌血清型的荚膜多糖 其中肺炎链球菌血清型选自：1,3,4,5,6A，6B，7F，9V，12F，14,18C，19A，19F，22F，23F和33F， 其中两种荚膜多糖与破伤风类毒素缀合，其余荚膜多糖与CRM 197缀合，并且其中与破伤风类毒素缀合的两种荚膜多糖选自血清型1 还提供了生产混合载体的方法，多价肺炎球菌缀合物组合物及其用于预防肺炎链球菌感染或疾病的方法 主题。
-
公开(公告)号：WO2017210592A1
公开(公告)日：2017-12-07
申请号：PCT/US2017/035738
申请日：2017-06-02
申请人： SANOFI PASTEUR INC.
发明人： STRUGNELL, Tod , OLOO, Eliud , OOMEN, Raymond
IPC分类号： C07K14/005
摘要： The present invention provides, among other things, modified recombinant HA polypeptides with broadened immunogenic profile that extends coverage to antigenically distinct influenza strains and methods of making and using the same.
摘要翻译： 本发明尤其提供了具有扩大的免疫原性谱的修饰的重组HA多肽，其将覆盖扩展至抗原性不同的流感病毒株及其制备和使用方法。
-
8.发明申请ENGINEERED INFLUENZA ANTIGENIC POLYPEPTIDES AND IMMUNOGENIC COMPOSITIONS THEREOF 审中-公开工程化的流感抗体多肽及其免疫组化
公开(公告)号：WO2016196846A2
公开(公告)日：2016-12-08
申请号：PCT/US2016/035594
申请日：2016-06-02
申请人： SANOFI PASTEUR INC.
发明人： STRUGNELL, Tod , OLOO, Eliud , OOMEN, Raymond
IPC分类号： C07K14/005
CPC分类号： C07K14/005 , C12N2760/16022 , C12N2760/16062
摘要： The present invention provides, among other things, a novel and improved method for generating "mosaic" influenza antigenic polypeptides including hemagglutinin (HA) and neuraminidase (NA) polypeptides based on unique combination of epitope patterns that maximize exposure to epitopes present across multiple HA or NA sequences and therefore improved influenza strain coverage. In particular, the present invention provides engineered H1N1 influenza hemagglutinin (HA) polypeptides that are comprised of novel combinations of protective epitopes and antigenic regions from multiple H1N1 viral strains. Such engineered HA polypeptides have improved properties over HA polypeptides developed through conventional approaches that rely on consensus alignments of viral sequences.
摘要翻译： 本发明尤其提供了一种用于产生包含血凝素（HA）和神经氨酸酶（NA））多肽的“镶嵌”流感病毒抗原多肽的新颖和改进的方法，所述方法基于使多个HA存在的表位最大化的表位图案的独特组合，或 NA序列，因此改善了流感病毒株的覆盖。 特别地，本发明提供了由多个H1N1病毒株的保护性表位和抗原区的新组合组成的工程H1N1流感血凝素（HA）多肽。 这样的工程化HA多肽比通过依赖于病毒序列的共有对准的常规方法开发的HA多肽具有改进的性质。
-
公开(公告)号：WO2014201346A1
公开(公告)日：2014-12-18
申请号：PCT/US2014/042298
申请日：2014-06-13
申请人： SANOFI PASTEUR INC.
CPC分类号： A61K39/08 , A61K2039/545 , A61K2039/55 , A61K2039/55511
摘要： This disclosure relates to methods for eliciting an immune response against C. difficile toxin A and toxin B in an adult human subject. The subject may be at risk for a primary symptomatic C. difficile infection. In some embodiments, a method is for eliciting an immune response against C. difficile toxin A and toxin B in an adult human subject at risk for a primary symptomatic C. difficile infection, and comprises administering to the subject a composition comprising C. difficile toxoid A and toxoid B at least three times, each administration being about seven days apart.
摘要翻译： 本公开涉及在成年人受试者中引发针对艰难梭菌毒素A和毒素B的免疫应答的方法。 受试者可能面临主要症状性艰难梭菌感染的风险。 在一些实施方案中，一种方法是在具有主要症状性艰难梭菌感染风险的成年人受试者中引发针对艰难梭菌毒素A和毒素B的免疫应答，并且包括向受试者施用包含艰难梭菌类毒素 A和类毒素B至少三次，每次给药约7天。
-
公开(公告)号：WO2014144567A3
公开(公告)日：2014-12-04
申请号：PCT/US2014029035
申请日：2014-03-14
申请人： SANOFI PASTEUR INC
发明人： HAUSER STEVEN
CPC分类号： A61K39/08 , A61K9/0019 , A61K9/19 , C07K14/33
摘要： The disclosure relates to generally to the field of toxin inactivation. More specifically, it relates to clostridial toxins, methods of inactivating these toxins and compositions (e.g., vaccines) comprising toxoids (e.g., produced by these methods). Provided are methods of producing a C. difficile toxoid comprising inactivating a C. difficile toxin with formaldehyde. Toxoids prepared by these methods are stable at high temperature (e.g., 37°C) and remain non-cytotoxic with minimal residual formaldehyde.
摘要翻译： 本公开一般涉及毒素灭活领域。 更具体地说，它涉及梭菌毒素，灭活这些毒素的方法和包含类毒素的组合物（例如，疫苗）（例如通过这些方法产生）。 提供了生产艰难梭菌毒素的方法，包括用甲醛灭活艰难梭菌毒素。 通过这些方法制备的毒素在高温（例如37℃）下是稳定的，并且以最小的残余甲醛保持非细胞毒性。
-
-
-
-
-
-
-
-
-
搜索结果
49 条记录 (耗时 0.024 秒)
